Wednesday, April 21, 2021 6:20:10 PM
OTCShotCaller, may I copy/paste the below from your post?
" Now here's something all of you should be aware of and likely are NOT, but I will educate you...only 5 in 5,000 New Patents for Drug development via filing an IND make it to the pre-clinical testing phase on human subjects. Then subsequently, of those 5, only 1 makes it past pre-clinical then onward to all phase completion preparing for treatment application which is the case with RGBP! FACT! If this was NOT the case they would NOT have been looked at twice by ANY BIG PHARMA!!! "
Am I deciphering correctly the above?
5 in 5000 patents...make it to pre-clinical.
1 of those 5 makes it past pre-clinical.
rgbp is past pre-clinical?
Must be something to it then?
Respects.
hl
" Now here's something all of you should be aware of and likely are NOT, but I will educate you...only 5 in 5,000 New Patents for Drug development via filing an IND make it to the pre-clinical testing phase on human subjects. Then subsequently, of those 5, only 1 makes it past pre-clinical then onward to all phase completion preparing for treatment application which is the case with RGBP! FACT! If this was NOT the case they would NOT have been looked at twice by ANY BIG PHARMA!!! "
Am I deciphering correctly the above?
5 in 5000 patents...make it to pre-clinical.
1 of those 5 makes it past pre-clinical.
rgbp is past pre-clinical?
Must be something to it then?
Respects.
hl
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
